SolveBio Awarded SBIR Phase I Grant from NIH for Genomic Intelligence Genetic Variant Analysis and Visualization Tool

NEW YORK--()--SolveBio, a contextual knowledge hub, announced today that the National Institutes of Health (NIH) has funded further development of the Variant Explorer, a genetic variation analysis and visualization system. SolveBio received a Phase I Small Business Innovation Research Grant from the National Institute of General Medical Sciences for the research and development grant, R43GM117644, entitled “The Variant Explorer: a cloud-based data integration and visualization system for improving clinical interpretation of sequenced genetic variants”. The funds will be used to develop the Variant Explorer as a decision support tool for clinical geneticists, molecular pathologists, and scientists in the pharmaceutical industry and at academic medical centers.

“The Variant Explorer: a cloud-based data integration and visualization system for improving clinical interpretation of sequenced genetic variants”

“The interpretation and analysis of interesting variants is now the single most intractable bottleneck in the next generation sequencing-based workflow.” said Dandan Xu, chief scientific officer at SolveBio and the principal scientist for the project. “The Variant Explorer is an interface to the SolveBio contextual knowledge hub for genetic variants that need to be evaluated and classified. The combination of curated and actionable data and an enjoyable user interface allows the scientist and clinician to evaluate genetic variants more efficiently and effectively. We see this advancement in information visualization and analysis as being integral to realizing the promise of precision medicine.”

About SolveBio

SolveBio, founded in 2013, is a contextual knowledge hub focused on enabling pharma, biotech, and diagnostic organizations to effectively connect and use external and internal genomic information. SolveBio extracts, evaluates, and unifies complex, disparate biomedical data for life science enterprises. SolveBio is based in New York and is backed by Andreessen Horowitz, Max Levchin, Nat Turner, SV Angel, Faridan Capital and other leading life sciences and technology investors. For more information, visit www.solvebio.com.

Contacts

SolveBio
Matt Marano, +1-401-743-3788
SVP Commercial Development
Matt@solvebio.com